Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells

Neoplasia (United States)

Volumn 14, Issue 6, 2012, Pages 463-475

  Lin, Yu Chin ^a,b,c   Wu, Meng Hsuan ^a   Wei, Tzu Tang ^a   Chung, Shu Hui ^a   Chen, Kuen Feng ^b   Cheng, Ann Lii ^b   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LYSOSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84865649644     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.12300     Document Type: Article

References (49)

1. Hynes NE and Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354.
2. Rubin Grandis J, Melhem MF, Barnes EL, and Tweardy DJ (1996). Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78, 1284-1292.
3. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, and Milas L (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62, 7350-7356.
4. Herbst RS and Langer CJ (2002). Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29, 27-36.
5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354, 567-578.
6. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359, 1116-1127.
7. Wang W, Dong L, Saville B, and Safe S (1999). Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NF-YSp1/estrogen receptor interactions. Mol Endocrinol 13, 1373-1387.
8. Watters JJ, Chun TY, Kim YN, Bertics PJ, and Gorski J (2000). Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol 14, 1872-1881.
9. Nemere I, Pietras RJ, and Blackmore PF (2003). Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 88, 438-445.
10. Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, and Sternberg H (2005). Caloric restriction reduces cell loss and maintains estrogen receptor-α immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. Neuro Endocrinol Lett 26, 197-203.
11. Jordan VC (1995). Third annual William L. McGuire Memorial Lecture. Studies on the estrogen receptor in breast cancer-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36, 267-285.
12. Ueo H, Matsuoka H, Sugimachi K, Kuwano H, Mori M, and Akiyoshi T (1990). Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res 50, 7212-7215.
13. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, and Siegfried JM (2005). Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65, 1459-1470.
14. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, and Stabile LP (2009). Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 15, 6529-6540.
15. Ahmed SM and Cohen EE (2007). Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets 7, 666-673.
16. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354, 2531-2541.
17. Talamonti MS, Roh MS, Curley SA, and Gallick GE (1993). Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer. J Clin Invest 91, 53-60.
18. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, and Gallick GE (2002). Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94, 344-351.
19. Johnson FM, Saigal B, Talpaz M, and Donato NJ (2005). Dasatinib (BMS354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11, 6924-6932.
20. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, et al. (2010). Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28, 4609-4615.
21. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, and Papadimitrakopoulou VA (2011). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117, 2112-2119.
22. Lin YC, Shun CT, Wu MS, and Chen CC (2006). A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-κB. Clin Cancer Res 12, 7165-7173.
23. Bromann PA, Korkaya H, and Courtneidge SA (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23, 7957-7968.
24. Hackel PO, Zwick E, Prenzel N, and Ullrich A (1999). Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11, 184-189.
25. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, et al. (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15, 3740-3750.
26. Authier F, Metioui M, Bell AW, and Mort JS (1999). Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem 274, 33723-33731.
27. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, and Lipkowitz S (2001). Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 276, 27677-27684.
28. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, and Madshus IH (2002). Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156, 843-854.
29. Le Roy C and Wrana JL (2005). Clathrinand non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6, 112-126.
30. Perillo B, Sasso A, Abbondanza C, and Palumbo G (2000). 17β-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20, 2890-2901.
31. Svotelis A, Bianco S, Madore J, Huppe G, Nordell-Markovits A, Mes-Masson AM, and Gevry N (2011). H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J 30, 3947-3961.
32. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
33. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417.
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792.
35. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, and Egloff AM (2011). Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs, In press.
36. Sen B, Peng S, Saigal B, Williams MD, and Johnson FM (2011). Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 17, 514-524.
37. Dulak AM, Gubish CT, Stabile LP, Henry C, and Siegfried JM (2011). HGF-independent potentiation of EGFR action by c-Met. Oncogene 30, 3625-3635.
38. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
39. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, and Nyati MK (2007). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26, 3431-3439.
40. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, and Nyati MK (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869.
41. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, et al. (2011). Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 17, 5755-5764.
42. Chou CW, Wu MS, Huang WC, and Chen CC (2011). HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 6, e18087.
43. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, and Nyati MK (2006). Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66, 981-988.
44. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351-362.
45. Karni R, Jove R, and Levitzki A (1999). Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18, 4654-4662.
46. Johnson FM, Saigal B, Tran H, and Donato NJ (2007). Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13, 4233-4244.
47. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, et al. (2007). Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. J Clin Invest 117, 2205-2215.
48. Osborne CK and Schiff R (2011). Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62, 233-247.
49. Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E, and Clapper ML (2011). Estrogen and cytochrome P450 1B1 contribute to both earlyand latestage head and neck carcinogenesis. Cancer Prev Res (Phila) 4, 107-115.